![]() 300009 3 weeks ago | Other | ¥0.15 Per Share |
![]() 300009 4 months ago | Other | ¥0.1 Per Share |
![]() 300009 27 May 2024 | Other | ¥0.25 Per Share |
![]() 300009 19 May 2023 | Other | ¥0.25 Per Share |
![]() 300009 13 May 2022 | Other | ¥0.2 Per Share |
18 Apr 2025 Date | | - Cons. EPS | - EPS |
28 Mar 2025 Date | | - Cons. EPS | 0.07 EPS |
24 Oct 2024 Date | | - Cons. EPS | 0.11 EPS |
28 Aug 2024 Date | | - Cons. EPS | 0.12 EPS |
25 Apr 2024 Date | | - Cons. EPS | 0.13 EPS |
![]() 300009 3 weeks ago | Other | ¥0.15 Per Share |
![]() 300009 4 months ago | Other | ¥0.1 Per Share |
![]() 300009 27 May 2024 | Other | ¥0.25 Per Share |
![]() 300009 19 May 2023 | Other | ¥0.25 Per Share |
![]() 300009 13 May 2022 | Other | ¥0.2 Per Share |
18 Apr 2025 Date | | - Cons. EPS | - EPS |
28 Mar 2025 Date | | - Cons. EPS | 0.07 EPS |
24 Oct 2024 Date | | - Cons. EPS | 0.11 EPS |
28 Aug 2024 Date | | - Cons. EPS | 0.12 EPS |
25 Apr 2024 Date | | - Cons. EPS | 0.13 EPS |
Biotechnology Industry | Healthcare Sector | Mr. Lihua Song Ph.D. CEO | XSHE Exchange | CNE100000GY2 ISIN |
CN Country | 2,647 Employees | - Last Dividend | 14 May 2021 Last Split | 30 Oct 2009 IPO Date |
Anhui Anke Biotechnology (Group) Co., Ltd., established in 2000 and headquartered in Hefei, China, specializes in the development, production, and international distribution of pharmaceutical products. The company focuses on a diverse range of therapeutic areas and biotechnological advancements, offering a wide spectrum of products from biopharmaceuticals to diagnostic kits and synthetic drugs. Anhui Anke Biotechnology is dedicated to leveraging its research and development capabilities to meet the evolving needs of the healthcare sector, both within China and globally.
The company manufactures and markets biopharmaceuticals such as human growth hormone injections (branded as Ansomone), recombinant human interferon alpha 2b in various forms (branded as Anterferon), and monoclonal antibody drugs, including Trastuzumab for breast and gastric cancers, Bevacizumab for non-small cell lung cancer, and anti-PD1 for advanced cancers.
Anhui Anke offers a range of diagnostic kits targeting various medical needs, such as anti-sperm antibody, semen analysis tests, sperm life detection, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostics. Additionally, they provide autosomal and sex chromosome testing kits, paternity testing packages, and professional DNA testing services.
The company produces synthetic drugs in oral powders, dripping pills, and tablets and capsules form. These medicinal products cater to a broad spectrum of therapeutic categories.
A range of beauty care products, including anti-aging treatments, masks, essential liquids, and mouthwash, are part of Anhui Anke's diversified portfolio, addressing the growing consumer demand for wellness and personal care items.
Topical products such as adhesive plasters, oral solutions, and ointments complement the therapeutic offerings of the company, providing solutions for both prescription and over-the-counter needs.
Anhui Anke also specializes in the development and manufacturing of Peptide Active Pharmaceutical Ingredients (APIs), serving the pharmaceutical industry's need for high-quality, research-backed ingredients.
This segment includes innovative treatments for cancer, utilizing biological responses and immunotherapy to combat tumor growth and spread, highlighting the company's commitment to advanced cancer treatment research.